Loading...

PerCP/Cyanine5.5 anti-mouse IFN-γ Antibody

Pricing & Availability
Clone
XMG1.2 (See other available formats)
Regulatory Status
RUO
Other Names
Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF)
Isotype
Rat IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
XMG1-2_PerCPCyanine55_IFN-y_Antibody_1_111924
PMA/Ionomycin-stimlated ( 6hrs ) C57BL/6 splenocytes surface stained with CD3ε (clone 145-2C11) APC and intracellularly stained with IFN-γ (clone XMG1.2) PerCP/Cyanine5.5
  • XMG1-2_PerCPCyanine55_IFN-y_Antibody_1_111924
    PMA/Ionomycin-stimlated ( 6hrs ) C57BL/6 splenocytes surface stained with CD3ε (clone 145-2C11) APC and intracellularly stained with IFN-γ (clone XMG1.2) PerCP/Cyanine5.5
Compare all formats See PerCP/Cyanine5.5 spectral data
Cat # Size Price Quantity Check Availability Save
505821 25 µg 95€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
505822 100 µg 259€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

IFN-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
E. coli-expressed, recombinant mouse IFN-γ
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Application Notes

ELISA1-4,11,14 or ELISPOT5 Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard.
ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812).
Flow Cytometry7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ-producing cells within mixed cell populations.
Neutralization1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-γ. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IFN-γ bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections6,22,23, and immunocytochemistry.
Note: For testing mouse IFN-γ in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430801 to 430806) are specially developed and recommended.

Application References

(PubMed link indicates BioLegend citation)
  1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut)
  2. Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut)
  3. Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut)
  4. Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA)
  5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT)
  6. Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC)
  7. Ferrick D, et al. 1995. Nature 373:255. (FC)
  8. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  9. Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut)
  10. DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut)
  11. Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA)
  12. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
  13. Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed
  14. Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed
  15. Montfort M, et al.2004. J. Immunol. 173:4084. PubMed
  16. Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed
  17. Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed
  18. Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed
  19. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  20. Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed
  21. Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed
  22. Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC)
  23. Mottram PL, et al. 1998. J Immunol. 161:602. (IHC)
Product Citations
  1. Schenkel JM, et al. 2021. Immunity. 54:2338. PubMed
  2. Campisi L, et al. 2022. Nature. 606:945. PubMed
  3. Wang W, et al. 2022. Cell Rep. 41:111582. PubMed
  4. Xie Z, et al. 2022. Cell Discov. 8:133. PubMed
  5. Kumpunya S, et al. 2023. Front Immunol. 13:1010764. PubMed
  6. Ding L, et al. 2023. J Clin Invest. 133: . PubMed
  7. Zhang W, et al. 2022. Front Cell Dev Biol. 10:842813. PubMed
  8. Li X, et al. 2023. J Clin Invest. 133:. PubMed
  9. Giampaolo S, et al. 2023. iScience. 26:106234. PubMed
  10. Bhaskar A, et al. 2023. iScience. 26:106644. PubMed
  11. Changsheng H, et al. 2023. Sci Adv. 9:eade4186. PubMed
  12. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  13. Wu T, et al. 2021. Mol Ther Oncolytics. 23:420. PubMed
  14. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  15. Koh CH, et al. 2020. Cancer Immunol Res. 8:698. PubMed
  16. Lee Y, et al. 2020. J Innate Immun. 1:. PubMed
  17. Chen H, et al. 2005. J Immunol. 175:591. PubMed
  18. Rodriguez-García A, et al. 2021. Nat Commun. 12:877. PubMed
  19. Matsumoto R, et al. 2021. Front Pharmacol. 12:715752. PubMed
  20. Luo Z, et al. 2020. Front Immunol. 0.883333333. PubMed
  21. Volkov A, et al. 2013. PLoS One. 8:60565. PubMed
  22. Li B, et al. 2015. Sci Rep. 5: 14793. PubMed
  23. Braun F, et al. 2015. PLoS One. 10: 0135444. PubMed
  24. Yin Q, et al. 2015. PLoS One. 10: 0137808. PubMed
  25. Wang F, et al. 2021. Cell Mol Gastroenterol Hepatol. 13:257. PubMed
  26. Zhang L, et al. 2021. Methods Mol Biol. 2388:175. PubMed
  27. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  28. Liao T, et al. 2017. Front Immunol. 8:1334. PubMed
  29. Coe D, et al. 2022. JCI Insight. 7:. PubMed
  30. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  31. Carty S, et al. 2014. PLoS One. 9:106659. PubMed
  32. Ye X, et al. 2021. Cancer Biol Med. Online ahead of print. PubMed
  33. Wang Z et al. 2018. Immunity. 49(1):80-92 . PubMed
  34. Zhang X, et al. 2021. Mol Cancer Res. 19:1076. PubMed
  35. Murray MP, et al. 2022. Cell Rep. 38:110209. PubMed
  36. Mansouri S, et al. 2020. Mucosal Immunol. 0.954861111. PubMed
  37. Benci JL et al. 2019. Cell. 178(4):933-948 . PubMed
  38. He Y, et al. 2017. J Autoimmun. 10.1016/j.jaut.2017.04.001. PubMed
  39. Li X, et al. 2016. MBio. 7: 02232-15. PubMed
  40. Lee J, et al. 2007. Nat Immunol. 8:181. PubMed
  41. Jeon Y, et al. 2015. PLoS One. 10: e0139845. PubMed
  42. Wawrzyniak M, et al. 2021. Pharmacol Res Perspect. 9:e00837. PubMed
  43. Sun Y, et al. 2020. J Immunol. 205:2649. PubMed
  44. Burger ML, et al. 2021. Cell. 184:4996. PubMed
  45. Wu R, et al. 2020. J Immunother Cancer. 8:00. PubMed
  46. Ikeda T, et al. 2014. PLoS One. 9:115198. PubMed
  47. Lei F, et al. 2012. J Vis Exp. 63: 3986. PubMed
RRID
AB_961359 (BioLegend Cat. No. 505821)
AB_961359 (BioLegend Cat. No. 505822)

Antigen Details

Structure
Cytokine; dimer; 40-80 kD (Mammalian)
Bioactivity
Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs
Cell Sources
CD8+ and CD4+ T cells, NK cells
Cell Targets
T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors
IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type
Tregs
Biology Area
Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.

Regulation
Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone
Gene ID
15978 View all products for this Gene ID
UniProt
View information about IFN-gamma on UniProt.org

Related FAQs

How stable is PerCP/Cyanine5.5 tandem as compared to PerCP alone?

PerCP/Cyanine5.5 is quite photostable and also better than PerCP alone in withstanding fixation.

Go To Top Version: 1    Revision Date: 11.30.2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account